U.S. markets closed

Soliton, Inc. (SOLY)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
20.65-0.05 (-0.24%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close20.70
Bid19.93 x 1300
Ask21.42 x 800
Day's Range20.50 - 20.70
52 Week Range6.81 - 22.55
Avg. Volume314,326
Market Cap445.968M
Beta (5Y Monthly)0.13
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Soliton, Inc.
    CUTR: Lowering target price to $50.00CUTERA INC has an Investment Rating of HOLD; a target price of $50.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Insider Monkey

    Soliton, Inc. (SOLY): Hedge Funds Are Snapping Up

    Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]

  • Zacks

    Soliton (SOLY) is in Overbought Territory: What's Next?

    Soliton (SOLY) has moved higher as of late, but there could definitely be trouble on the horizon for this company

  • SmarterAnalyst

    AbbVie Unit To Acquire Soliton For $550M To Boost Aesthetics Unit

    AbbVie’s (ABBV) Allergan Aesthetics is to acquire Soliton (SOLY) plus its Rapid Acoustic Pulse device, which was recently approved by the U.S. Food and Drug Administration (FDA). The acquisition will expand the company’s body contouring treatment portfolio. The acquisition is built around Resonic, the Rapid Acoustic Pulse device that uses rapid pulses of acoustic shockwaves to help fade unwanted tattoo ink. It also helps in disintegrating fat deposits for short-term improvement in cellulite appearance. The technology is poised to address a massive unmet need in modifying the appearance of cellulite. “The addition of this technology complements Allergan Aesthetics' portfolio of body contouring treatments. Health care providers will now have another option to address consumers' aesthetic concerns”, said AbbVie Senior Vice President Carrie Strom. Under the terms of the deal, the AbbVie unit is to pay $22.60 per share for each Soliton’s outstanding shares, valuing the deal at about $550 million. The two companies’ boards of directors have already approved the transaction. The deal should be sealed upon fulfillment of customary closing conditions. The acquisition of Soliton comes on the heels of AbbVie's report of impressive Q1 2021 results, with sales and earnings coming in above estimates. Mizuho Securities analyst Vamil Divan has since reiterated a Buy rating on the stock, citing results that beat expectations. (See AbbVie stock analysis on TipRanks). “With a diversified new product story, robust near-term growth and good visibility into its longer-term growth prospects, we continue to see AbbVie as an especially compelling investment opportunity, especially when one considers the discount it trades at and its robust dividend,” Divan wrote. Divan has a $128 price target on the stock implying 10.14% upside potential to current levels. Consensus among analysts on Wall Street is a Strong Buy based on 10 Buys and 2 Holds. The average analyst price target of $126 implies 8.42% upside potential to current levels. ABBV scores an 8 out of 10 on the TipRanks’ Smart Score rating system, implying it is well-positioned to outperform the overall market. Related News: Cigna’s Earnings Beat Expectations, 2021 Outlook Raised Apollo Global's 1Q Results Shatter Records, Dividend Confirmed Royal Dutch Shell Consortium To Receive $2.4B For Carbon Capture Project - Report More recent articles from Smarter Analyst: MKS Instruments Acquires Photon For C$387M, Boost Technology Solutions Repay Holdings Snaps Up BillingTree For $503M Dish Network Taps Debt Market To Raise $1.25B For Broadcast Unit Biogen Collaborates With Capsigen To Develop New Gene Therapies